Get started
Author

Sophie Le Lamer-Déchamps

Observed names: Le Lamer Deschamps, Sophie, Le Lamer-Déchamps, Sophie, S Le Lamer-Déchamps, Sophie Le Lamer-Deschamps
Institution: MedinCell (France)
ORCID: 0000-0003-3074-4898
Observed ORCID: 0000-0003-3074-4898
OpenAlex ID: A5034101316
Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2018 · Wilhem Leconet, He Liu, et al. · Molecular Cancer Therapeutics · 47
Impact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology
2021 · Charlotte Molinier, Marina Picot-Groz, et al. · Journal of Controlled Release · 14
Validation of an inductively coupled plasma-mass spectrometry method to quantify tungsten in human plasma. Determination of percentage binding to plasma proteins
2002 · Sophie Le Lamer-Déchamps, Patrick Poucheret, et al. · Clinica Chimica Acta · 10
Influence of food and diabetes on pharmacokinetics of sodium tungstate in rat
2002 · S Le Lamer-Déchamps, P Poucheret, et al. · International Journal of Pharmaceutics · 7
Modelling the impact of ivermectin-based optimal strategies on malaria control: the role of formulation, coverage, and mosquitocidal efficacy timing
2026 · Franck J. Dongmo, Angelique Porciani, et al. · EBioMedicine · 4
Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions
2026 · Lamidi Zela, Sié Hermann Pooda, et al. · Parasites & Vectors · 3
PDF
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso
2026 · Cheick Oumar W. Ouédraogo, Fabrice A. Somé, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Evaluating the potential of a long-acting injectable ivermectin formulation in cattle against Greater Mekong Subregion Anopheles
2026 · Kevin C. Kobylinski, Nakarin Rachmarong, et al. · Research Square
PDF
Additional file 2 of Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions
2026 · Zela, Lamidi, Pooda, Sié Hermann, et al. · Figshare
Additional file 1 of Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions
2026 · Zela, Lamidi, Pooda, Sié Hermann, et al. · Figshare
Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions
2026 · Zela, Lamidi, Pooda, Sié Hermann, et al. · Figshare
Comparing Ivermectin susceptibility in wild-derived and laboratory-reared Aedes and Anopheles larvae: Preliminary study on selecting for resistance mechanisms
2024 · Ouedraogo, Cheick Oumar W., Sougue, Emmanuel, Daouda, et al. · HAL
Figure S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
Figure S2 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
Table S5 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
PDF
Table S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
Table S2 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
Table S3 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
PDF
Table S4 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
PDF
Figure S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
PDF
Figure S2 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
PDF
Data from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
Data from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
2023 · Wilhem Leconet, He Liu, et al.
Utilisation de la pharmacocinetique de population dans le développement préclinique d'un nouvel antidiabètique : le tungstate de sodium
2002 · Sophie Le Lamer-Deschamps · OpenGrey (Institut de l'Information Scientifique et Technique)
Works count: 24
Citation count: 86
H-index: 4
I10-index: 3
Year
Topic
Type